NCT00535743View on ClinicalTrials.gov

Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

March 4, 2004

Primary Completion Date

July 20, 2004

Study Completion Date

July 20, 2004

Conditions
Anesthesia, General
Interventions
DRUG

Sugammadex

Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.

DRUG

Placebo

0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,

DRUG

Esmeron®

Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00535743 - Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) | Biotech Hunter | Biotech Hunter